Investors apparently aren't too impressed with Cubist Pharmaceuticals' (CBST -2.6%) new...


Investors apparently aren't too impressed with Cubist Pharmaceuticals' (CBST -2.6%) new five-year strategic plan. CBST says it expects to boost global revenue to $2B annually, have four product candidates in late-stage clinical trials, and generate $700M in non-GAAP annual adjusted operating income.

From other sites
Comments (1)
  • EPButler
    , contributor
    Comments (3) | Send Message
     
    It can't double everyday, but Cubist is and has been doing pretty darned good. They not only had the one product with FDA approval last year, but have few others in close proximity. They were heavily considered for a buyout, and as their other products come closer to approval, should attract a lot of attention from the big boys again (even though they don't realy need be bought out).
    This has been and remains a money maker in my book
    11 Jun 2012, 03:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs